HALOZYME THERAPEUTICS, INC. · Biotech

HALO

Moderate riskNext report: In 5 days (est.)

View price ↗

The short version

A profitable company with growing sales. Institutions are adding.

Going well

Sales up 48% in the latest quarter vs a year ago
Profitable, keeps 23% of sales as profit
Sales up 38% last year

Watch out for

High debt: 43.89x equity

Money moves

Insiders sold $7.2M in the last 30 days, all through pre-planned sales
Institutions added 3.3% to their holdings in the quarter ending June 2026 (365 bought, 269 sold)
Held by Ray Dalio (Bridgewater)

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$127.96+1.9% that day

Company value: $14.5B; Share price times all shares
Price vs profit (P/E): 37.3x; You pay about $37 for each $1 of yearly profit
Price vs sales: 8.7x; Company value is 8.7 times a year of sales
Cash vs value: 1%; Cash as a share of company value
Debt vs value: 15%; Debt as a share of company value

From HALO's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 12 quarters, from SEC filings

Sales, Jun '26

$481.0M+48% vs a year earlier

Sep '23Tap a barJun '26

Last 12 months: $1.7B, up 41% from the 12 months before. Over 5 years, sales grew about 39% a year.

What the price assumes

Your guesses, our math

Move the sliders to your own view of HALO. Starting points are the company's recent numbers.

Sales growth+30% a yearRecently: +41% a yearProfit margin25%Last 12 months: 24.9%P/E at the end37xToday: 37.3x. Many steady companies trade at 12x to 25xShare count change-4% a yearBelow zero means buybacks; above zero means new shares (dilution)

Sales in 5 years$6.2B

Profit in 5 years$1.5B

Price these guesses point to$617.45+383% vs $127.96 todayAbout +37% a year, before dividends

What today's price needs: with a 25% margin and a 37x P/E, sales could shrink about 5.1% a year for 5 years and still match today's price.

Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

4/6Mixed

PassReturn on equity 15%+Earns a lot on the money owners have in the business.153.6%
MissDebt under half of equityNot relying on borrowed money.43.89x equity
PassNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.22.7%
MissProfitable every yearSteady profits, not one good year.7 of 10 years
PassFree cash flow positiveBrings in more cash than it spends to run and grow.$644.6M
PassShare count not growingNot diluting owners. Falling means buybacks.-11.9% in 3 years

Revenue: $1.4B; +37.6% vs prior year
5-year growth: +39.2%/yr; revenue, per year
Total debt: $2.1B; 43.89x equity
Current ratio: 4.66x; short-term assets / bills due

From annual reports filed with the SEC. Not in this company's SEC data, so not scored: gross margin 40%+. A checklist is a starting point for research, not a verdict.

Latest quarter

Quarter ended Jun 30, 2026

Reported Aug 6

Revenue: $481.0M; +47.7% YoY
EPS: $1.90; vs $1.33
Op. margin: 59.8%; -2.4 pts
Gross margin: 83.5%; -2.3 pts
Free cash flow: $236.7M
Share count: -2.4%; vs a year ago

Insider rating

Last 90 days

43Mixed

Pre-planned sales of $7.2M (weaker signal)

50 is neutral. Buying by more insiders, top executives and bigger stakes raises it. Selling lowers it; pre-planned sales count less.

Weekly insider trend

13 weeks agoBoughtSoldThis week

Filing buzz

Last 7 days vs normal

0/ 100

This week: 0
Normal week: 1.7
vs normal: 0.0x

SEC filings of any kind. 50 means a normal week.

Institutional ownership

Accumulating+3.3%

Institutions added 3.3% to their holdings. 365 bought, 269 sold.

Shares held by institutions124.2M

Sep '24Jun '26

Safety check

From SEC filings

Share count growthYearly rate, last 3 years

-4.9%

Cash runwayAt last year's cash burn

Cash flow positive

Debt to equityLatest balance sheet: debt compared with what owners have

14.9x · $2.1B debt

Shares outstandingLatest reported

113M

Why moderate risk

High debt: 14.95x equity
1 offering filing in 6 months (may sell new shares)

Earnings reports

Last 12

Next reportIn 5 days (est.)Estimated from the same quarter last year

Results filedAug 6
Results filedMay 11
Results filedFeb 17
Results filedJan 28
Results filedNov 3, 2025

Flags and big holders

Offerings 6 months, flags 12 months, holders 90 days

Major agreementSep 22 · View filing ↗Offering

Insider trades

Open-market buys and sells, last 90 days

Bought$00 insiders

Sold$7.2M2 insiders, 2 pre-planned

Insider	Trade	Shares	Avg price	Value	Owns after	Date
Helen TorleyPRESIDENT AND CEO	Sell	60K	$110.18	$6.6M	768K	Oct 8Filing ↗
-7.2% of their holdings $107.90 to $113.69 across 12 trades Traded Oct 6 to Oct 8 Pre-planned sale (10b5-1) Also Director Filed same day
Matthew L. PosardDirector	Sell	5K	$108.54	$568K	54K	Oct 1Filing ↗
-8.9% of their holdings $107.17 to $110.04 across 4 trades Pre-planned sale (10b5-1) Filed 1 day after